Table 4.
Total (n = 136) | TRZ (n = 77) | MYL-1401O (n = 59) | p-Value | |
---|---|---|---|---|
tpCR—Yes | 52 (38.2%) | 31 (40.3%) | 21 (35.6%) | 0.598 |
tpCR—No | 84 (61.8%) | 46 (59.7%) | 38 (64.4%) |
TRZ (reference trastuzumab), tpCR (total pathological complete response).
Total (n = 136) | TRZ (n = 77) | MYL-1401O (n = 59) | p-Value | |
---|---|---|---|---|
tpCR—Yes | 52 (38.2%) | 31 (40.3%) | 21 (35.6%) | 0.598 |
tpCR—No | 84 (61.8%) | 46 (59.7%) | 38 (64.4%) |
TRZ (reference trastuzumab), tpCR (total pathological complete response).